Allspring Global Investments Holdings LLC Has $1.99 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Allspring Global Investments Holdings LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,673 shares of the company’s stock after selling 64 shares during the period. Allspring Global Investments Holdings LLC’s holdings in IDEXX Laboratories were worth $1,993,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Alta Advisers Ltd acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $202,000. Valley Brook Capital Group Inc. acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $228,000. Vanguard Personalized Indexing Management LLC lifted its stake in IDEXX Laboratories by 6.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 14,190 shares of the company’s stock valued at $7,612,000 after purchasing an additional 848 shares during the last quarter. Sovereign Financial Group Inc. bought a new position in IDEXX Laboratories in the 2nd quarter valued at approximately $214,000. Finally, Concurrent Investment Advisors LLC lifted its stake in IDEXX Laboratories by 8.7% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 1,489 shares of the company’s stock valued at $799,000 after purchasing an additional 119 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $637.13 on Wednesday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The firm has a fifty day simple moving average of $639.51 and a 200 day simple moving average of $553.52. The company has a market capitalization of $50.97 billion, a PE ratio of 53.05, a P/E/G ratio of 4.17 and a beta of 1.58. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter last year, the firm earned $2.44 earnings per share. IDEXX Laboratories’s quarterly revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 406 shares of IDEXX Laboratories stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the sale, the executive vice president directly owned 11,287 shares of the company’s stock, valued at approximately $7,336,098.52. The trade was a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the sale, the director directly owned 262 shares of the company’s stock, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on IDXX shares. Weiss Ratings reissued a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday, October 8th. Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a research note on Tuesday, July 1st. They set a “buy” rating and a $625.00 price target for the company. Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a report on Friday, August 15th. UBS Group began coverage on shares of IDEXX Laboratories in a report on Wednesday, October 1st. They set a “neutral” rating and a $720.00 price target on the stock. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $656.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.